During his time at TScan Therapeutics, David Southwell's holdings in the company's stock showed considerable growth, peaking at about $5.72 million in March 2021. However, this value fluctuated significantly, dropping below $3 million in subsequent months. By the time he...
During his time at TScan Therapeutics, David Southwell's holdings in the company's stock showed considerable growth, peaking at about $5.72 million in March 2021. However, this value fluctuated significantly, dropping below $3 million in subsequent months. By the time he stepped down, he had seen a decline in his stock value due to a lack of vested rewards and options in 2023. The peak values indicate he actively traded, reflecting an insightful approach to managing his investments in a biotech firm navigating the challenges of product development and clinical trials. This wealth in TScan stock went from less than $1.15 million in late 2019, and steadily rose as the company made strides toward innovation, hitting a high of $5.49 million shortly before his exit.